Glycogen storage disease type Ia (GSD-Ia) stems from glucose-6-phosphatase (G6Pase) deficiency and causes hypoglycemia, hepatomegaly, hypercholesterolemia and lactic acidemia. Three dogs with GSD-Ia were initially treated with a helper-dependent adenovirus encoding a human G6Pase transgene (HDAd-cG6Pase serotype 5) on postnatal day 3. Unlike untreated dogs with GSD-Ia, all three dogs initially maintained normal blood glucose levels. After 6-22 months, vector-treated dogs developed hypoglycemia, anorexia and lethargy, suggesting that the HDAd-cG6Pase serotype 5 vector had lost efficacy. Liver biopsies collected at this time revealed significantly elevated hepatic G6Pase activity and reduced glycogen content, when compared with affected dogs treated only by frequent feeding. Subsequently, the HDAd-cG6Pase serotype 2 vector was administered to two dogs, and hypoglycemia was reversed; however, renal dysfunction and recurrent hypoglycemia complicated their management. Administration of a serotype 2 HDAd vector prolonged survival in one GSD-Ia dog to 12 months of age and 36 months of age in the other, but the persistence of long-term complications limited HDAd vectors in the canine model for GSD-Ia.
INTRODUCTION
Glycogen storage disease (GSD) type Ia, or von Gierke disease, is an autosomal recessive disorder caused by a deficiency in glucose-6-phophatase (G6Pase). GSD-Ia patients lack a functional G6Pase enzyme and are unable to convert glucose-6-phosphate into free glucose, resulting in decreased hepatic glucose production, excess hepatic glycogen accumulation and increased concentrations of hepatic glucose-6-phosphate. 1 The glycolytic pathway predominates in these patients and excess glucose-6-phosphate is ultimately converted into pyruvate and lactate. Therefore, patients with GSD-Ia often present with hypoglycemia and lactic acidemia during infancy, often presenting with hypoglycemic seizures after 6 to 8 months of life. 1 Hypercholesterolemia occurs in patients with GSD-Ia, resulting from increased lipolysis due to decreased hepatic glucose production. 1, 2 Another major manifestation of GSD-Ia is hepatomegaly, and the liver of patients with GSD-Ia can represent 20% of their body weight. 2 The increased glycolytic activity and the accompanying production of lactate and pyruvate results in the production of substrates (acetylCoA, glycerol) and cofactors (nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate), which ultimately leads to increased lipid synthesis. 2 Increased lipid synthesis results in fatty deposits, primarily in the liver, which contributes to hepatomegaly. Hepatomegaly may be present at birth or becomes detectable during infancy. 1 Patients with GSD-Ia also exhibit moderate-to-severe growth retardation, doll-like faces and a short stature with relatively thin extremities. 1 The first naturally occurring G6Pase mutation in animals was identified by Brix et al., 3 when two 47-day-old littermate Maltese puppies presented with a history of failure to thrive, lethargy, distended abdomen, and grossly enlarged, pale livers. A novel GSD-Ia dog model was established by crossbreeding male Maltese dogs that carried the mutant G6Pase-a allele with Beagles. 4 Much like humans with GSD-Ia, affected Maltese-Beagle puppies exhibit hypoglycemia, growth retardation, hepatomegaly, hypercholesterolemia, hypertriglyceridemia and lactic acidemia. Affected GSD-Ia puppies have decreased G6Pase activity and increased glycogen content in liver and kidney, when compared with normal puppies.
Currently, there is no effective treatment for GSD-Ia other than dietary therapy, and non-adherence to dietary therapy can be fatal. 1, 2 Management of hypoglycemia by supplementation with daily, intermittent uncooked cornstarch and frequent feeding remain standard therapies for patients with GSD-Ia. 5 While dietary management can be effective at maintaining euglycemia, biochemical abnormalities including intermittent hypoglycemia, hypercholesterolemia and lactic acidemia persist. 1 Dietary therapy fails to prevent long-term complications including short stature, renal dysfunction and hepatic adenomas in many affected patients. 6 New therapies, including gene therapy, are under development for GSD-Ia. Effective gene therapy should maintain stable, long-term transgene expression in the involved tissues, especially the liver and kidney. Previous experiments using an adeno-associated virus (AAV) serotype 2 vector transiently corrected serum cholesterol, serum triglyceride and plasma lactate levels and increased hepatic G6Pase levels after 8 weeks of age in dogs with GSD-Ia. 7 Another experiment using an AAV2 vector pseudotyped as AAV8 (AAV2/8), which contained a human G6Pase transgene, prolonged the survival of three dogs to 411 months and prevented hypoglycemia following a 2-h fast. 8 At the first month of age, plasma lactate and serum cholesterol and triglyceride levels for the three dogs were within the reference range for normal, unaffected dogs. Liver biopsies performed in the AAV2/8-treated dogs at 4 months of age showed increased hepatic G6Pase levels and decreased hepatic glycogen. Observed levels were equivalent to those observed in normal dogs, indicative of widespread hepatic transgene expression. Despite this very encouraging initial data, more recently it has become evident that eventually GSD-Ia dogs treated with an AAV2/8 vector will eventually need to be treated again when transgene expression wanes. 9 Helper-dependent adenovirus (HDAd) vectors have emerged as promising candidates for gene therapy. This Ad-based vector has all viral coding sequences removed, leaving only sequences for packaging and vector propagation. 10 HDAd vectors derived from human Ad serotype 5 preferentially transduce the liver, where infection efficacy rates may approach 100%. 11 Baboons and mice given a single dose of an HDAd vector had appreciable hepatic transgene expression, lasting 1-2.5 years. [11] [12] [13] [14] [15] Because of the long-term transgene expression and relatively low toxicity, in comparison with first generation Ad vectors, HDAd vectors present an attractive candidate for the development of gene therapy for inherited disorders such as GSD-Ia.
While there has been extensive research of the immediate and intermediate effects of vector-mediated therapies in the murine and canine model of GSD-Ia, there is little information evaluating the longer-term efficacy of these vector-mediated therapies. The key objectives of this study were to demonstrate the efficacy of HDAd gene therapy as a primary treatment of GSD-Ia using the dog model, and to evaluate the effects of readministration of an HDAd vector of a new serotype. End points included the prevention of hypoglycemia during fasting, and the correction of other biochemical and clinical abnormalities associated with GSD-Ia.
RESULTS
HDAd-G6Pase vector-mediated gene therapy prolonged survival in dogs with GSD-Ia Three puppies affected with GSD-Ia were treated with a serotype 5 HDAd-cG6Pase vector (2Â10 12 vp kg -1 body weight) on postnatal day 3 ( Table 1 ). The first treated puppy, dog H, developed hypoglycemia during fasting (2-3 h) during the first few days following vector administration. The HDAd vector did not cause toxicity 1 day following vector administration in unaffected littermates, previously reported as thrombocytopenia and elevated serum alanine aminotransferase (Table 2) , in contrast to previous report of hepatotoxicity following administration of an HDAd vector. 16 Moreover, fasting blood glucose levels stabilized within the normal range for dog H in the weeks following vector administration (Figure 1a) . In contrast, affected dogs treated with diet alone had significantly reduced blood glucose levels within 2 h of eating (25±12 mg dl -1 ; n¼18 observations of four affected dogs ages 1-141 days of life). Despite correction of hypoglycemia, serum analysis usually revealed hypercholesterolemia and lactic acidemia following a 2-h fast (Figures 1b and c) . Approximately 20 months after the initial HDAd vector administration, dog H presented with recurrent hypoglycemia (manifesting as ataxia and facial twitching), and anorexia. Supplemental use of dextrose on a daily basis (three to four times a day) and a decreased blood glucose level after 2-3 h of fasting prompted the administration of a second vector at 22 months of age, HDAD-cG6Pase serotype 2 (1Â10 12 vp kg -1 ). The serotype was changed to Ad2 to avoid previously formed anti-Ad5 antibodies, even though the titer for anti-Ad5 was low at 1:10 (Table 1) . During the second week following rescue vector administration, dog H was more active, ate normally and maintained blood glucose levels in the normal range. The initial injection of the HDAd-cG6Pase serotype 5 vector followed by injection of the HDAd-cG6Pase serotype 2 vector prolonged survival of dog H for 36 months. In comparison, untreated GSD-Ia dogs die within 2 months. 8 Like dog H, dog E was treated with the HDAd-cG6Pase serotype 5 vector on postnatal day 3. For the first few months of life, blood glucose levels remained within the normal range during fasting ( Figure 1a) ; however, intermittent lactic academia and hypercholesterolemia were present (Figures 1b and c) . At 6 months of age, dog E became inactive, anorexic and failed to maintain a normal blood glucose level during fasting (Figure 1a) . Despite initiation of feeding every 4 h, symptoms of hypoglycemia persisted. Therefore, the After initial vector injection and subsequent rescue vector injection, HDAd-cG6Pase vector-treated dogs with GSD-Ia retained lactic acidemia. Plasma lactate levels were initially increased, followed by a sharp decrease for dog H (Figure 1b) . Plasma lactate levels for dog E were initially decreased to the normal range, followed by a sharp increase (Figure 1b) . Overall, lactate levels seen in the HDAd-cG6Pase vector-treated dogs were generally outside the reference range of 0.4-3.0 mmol l -1 . Cholesterol levels were also increased for vectortreated GSD-Ia after the first few months of age, although dog H's cholesterol level approached the normal range frequently (Figure 1c) . The affected dogs grew slowly, when compared with their unaffected (carrier and wild-type) littermates. The initial body weight of the vector-treated dogs was B250 g. By 30 days of age, vector-treated GSD-Ia dogs weighed between 500 and 750 g, whereas unaffected littermates weighed B50% more (945 ± 127 g; n¼16).
Before administration of the second vector to dogs H and E, a liver biopsy was obtained. Analysis of liver biopsy samples revealed significantly increased hepatic G6Pase levels (Figure 2a ), in comparison with affected dogs that received no vector (P¼0.002). Glycogen content of the liver was decreased by 95%, reaching the level observed in normal dogs that served as normal controls (Figure 2b ; P¼0.006). Both human and canine carriers for GSD-Ia maintain normal blood glucose during fasting for several hours, and do not accumulate glycogen in the liver. 1, 8, 9 Following a single neonatal administration of HDAd-cG6Pase vector, HDAd-treated dogs E and H with GSD-Ia had B20% of hepatic G6Pase activity observed in normal dogs (1.9 ± 0.2 mmol g -1 ), when biopsied at 7 and 22 months of age, respectively. GSD-Ia dogs that were maintained solely with diet demonstrated hepatic G6Pase activity of 0.48±0.18 mmol g -1 tissue per minute, B7% of normal's hepatic G6Pase activity ( Figure 2a) . Dogs E and H developed complications that met humane end points at 12 and 36 months of age, respectively, and postmortem samples of liver and kidney were analyzed for biochemical correction. The analysis of G6Pase activity and glycogen content from postmortem tissue revealed that biochemical correction of liver, but not kidney, which persisted for the lifetime of the treated dogs. For purposes of comparison, a third puppy treated on postnatal day 3 with HDAd-cG6Pase serotype 5 (2Â10 12 vp kg -1 ) was analyzed (dog M). This third HDAd-treated dog had a single blood glucose elevated to the normal range (70 mg dl -1 ) during fasting at 1 month of age, but an accident with tube feeding caused aspiration and early demise at 5 weeks of age. Liver G6Pase activity in HDAd-treated dogs with GSD-Ia persisted at B20% of the level observed in normal dogs, although it was not significantly elevated from the background level observed in untreated, affected dog liver (Figure 2a ). Correction of glycogen storage was demonstrated by decreased liver glycogen content in vector-treated affected dog liver, in comparison with untreated, affected dog liver (Figure 2b ). Real-time polymerase chain reaction (PCR) quantification of HDAd vector genomes revealed a gradual loss of vector genomes with increased age (Figure 2c ). These data suggested that transduction with the HDAd vector decreased during the months following vector administration, because the youngest dog, M, retained the highest number of vector genomes in the liver (Figure 2c ). Kidney G6Pase activity was equivalent to the level previously observed in affected puppies (Figure 2d ), whereas kidney glycogen content remained highly elevated consistent with a lack of kidney transduction ( Figure 2e ).
The efficacy of gene therapy in GSD-Ia can be further evaluated by prolonged fasting, and monitoring blood glucose and lactate at intervals. Dog H was evaluated by fasting for 6 h at 563, 935 and 1041 days of age ( Figure 3 ). Blood glucose remained normal for 44 h at 563 days, and for 46 h at 935 days (Figure 3a) . The latter result was presumably improved by administration of the HDAd-cG6Pase serotype 2 vector at 22 months. Blood lactate was elevated at all three time points, and was higher with increasing age (Figure 3b ).
Intriguingly, blood lactate did not increase with prolonged fasting, indicating that metabolic decompensation was prevented. 17 Later, after 1041 days of age, blood glucose dropped after 2 h of fasting, suggesting that the efficacy from vector administration was waning (Figure 3a ).
Long-term complications of GSD-Ia in affected dogs
We have previously reported that canine GSD-Ia caused very high mortality, when treated with conventional dietary therapy consisting of frequent feedings. 4, 8, 9 The original colony established for characterization of the natural history for canine GSD-Ia confirmed abnormalities consisting of recurrent hypoglycemia, persistent lactic academia and hypercholesterolemia, and glycogen accumulations in liver and kidney. 4, 18 Renal involvement was further confirmed by the presence of focal glomerulosclerosis, 4 which is typical of GSD-Ia. 19, 20 The longterm survival of four affected dogs allowed long-term complications similar to those observed in human patients with GSD-Ia to develop.
Only one of the eight affected dogs survived for 42 months, demonstrating very high mortality despite initiation of dietary therapy. 8 A single GSD-Ia dog survived with routine care until 2 years of age with very few episodes of hypoglycemia, which was attributed to a strong appetite and frequent eating. Other GSD-Ia dogs consistently developed anorexia in the absence of biochemical correction with gene therapy. However, hypoglycemia, lactic acidemia and hypercholesterolemia were present during fasting, and pathological proteinuria accompanied by declining physical condition necessitated euthanasia. Postmortem examination revealed hepatomegaly without any liver masses, and nephromegaly. Microscopically, there was cytopathic vacuolation of hepatocytes in the liver and cortical tubule cells in the kidney typical for GSD-Ia 4 (not shown).
Dog H was treated with HDAd-cG6Pase serotype 2 and 5 vectors as described above, and apparently developed acute hypoglycemia leading to demise at 36 months of age. Before this fatal episode, he was able to maintain normal blood glucose during fasting 44 h at 31 months of age. Postmortem examination revealed that dog H was found to have microscopic changes typical of advanced GSD-Ia in the liver and kidney. Microscopically, there was evidence of adenoma development, consisting of circumscribed foci of hepatocellular proliferation with slight compression of adjacent hepatic parenchyma that suggested preneoplastic lesions (Figures 4a and b) . Consistent with a loss of transgene expression, there was generalized cytoplasmic vacuolation of hepatocytes in dog H's liver (Figure 4b) . Dog E also was found to have cytoplasmic vacuolation of hepatocytes (Figure 4c) . Furthermore, dog E had severe abnormalities of the kidney, including glomerulosclerosis and cortical tubule cytoplasmic vacuolation. (Figures 4e and f) . The proximal convoluted tubules around glomeruli were most severely affected. In both kidneys of dog H, there was diffuse, moderate cytoplasmic vacuolation of moderate numbers of cortical tubules, primarily involving proximal convoluted tubules, which is typical of the involvement of kidney in GSD-Ia (Figure 4g ). Glycogen staining of liver revealed that storage of glycogen was reduced in dog H's liver at 3 years of age, in comparison with the liver of the above-mentioned 2-year-old GSD-Ia dog treated with diet alone (Figures 4i and j) , consistent with biochemical evidence of hepatic correction (Figure 2) .
At almost 1 year of age, dog E developed symptoms consisting of low activity and emesis, in association with persistent hypoglycemia. Renal failure was diagnosed based upon highly elevated serum BUN (blood urea nitrogen) and creatinine (Figures 5a and b) , which responded only to aggressive intravenous hydration and prompted euthanasia according to the guidelines for humane end points. Dog H was confirmed to have renal insufficiency, based upon elevated serum creatinine and BUN after 30 months of age (Figures 5c and d) . Evidence of a humor immune response in the form of anti-Ad2 antibodies were present at an elevated titer of 1:800 in dog E following the administration of HDAd serotype 2, whereas anti-Ad5 antibodies remained at low titer in both dogs E and H (Table 1) . No lymphocytic infiltrates were detected in the liver in either dog, which would have implicated a cellular immune response to HDAd (Figure 4 and data not shown).
DISCUSSION
This study demonstrated that the use of the HDAd-cG6Pase vector prolonged survival and prevented hypoglycemia in dogs with GSD-Ia. An initial HDAd-cG6Pase serotype 5 vector-treated dog was protected from hypoglycemia for 422 months, and was successfully retreated with the serotype 2 HDAd vector for an additional 12 months before developing recurrent hypoglycemia. Another GSD-Ia dog treated with both serotype 5 and 2 HDAd vectors survived until 12 months of age and then was euthanized as a result of renal complications associated with the GSD-Ia disease. The survival of these dogs with GSD-Ia can be viewed as a success, because early mortality usually cannot be prevented by any other treatment than efficacious gene therapy in this disorder. 4, [7] [8] [9] The reversal of hypoglycemia following the initial administration of HDAd, in comparison with untreated dogs, and prevention of hypoglycemia is the end point most relevant to human GSD-Ia. The reversal of hypoglycemia following vector readministration confirmed the efficacy of the second, serotype 2 HDAd vector. Furthermore, GSD-Ia is a GSD involving the liver and kidney, and the reversal of glycogen storage in the liver is the second very significant abnormality that was corrected by HDAd administration.
One of the limitations associated with gene therapy is a waning effect of transgene expression over time after initial vector injection, which has been encountered previously with an AAV2/8 vector in canine GSD-Ia by another group. 9 In contrast to the experience reported with a small genome AAV2/8 vector that could be packaged as double-stranded AAV2/8 and prolonged survival for 411 months in three consecutive dogs with GSD-Ia, Weinstein et al. reported that a single-stranded AAV2/8 vector failed to prevent hypoglycemia for 42 months of age in one dog with GSD-Ia. With regard to neonatal administration of the current HDAd-cG6Pase serotype 5 vector, it performed favorably in that symptoms were prevented for 6-22 months in two consecutive dogs with GSD-Ia. Although liver biopsies prior to second vector administration revealed increased G6Pase levels, clinical signs (that is, decreased fasting blood glucose, anorexia and decreased activity) suggested that the transgene efficacy was waning before administration of the HDAd-cG6Pase serotype 2 vector as a rescue vector. We theorize that following the initial HDAd vector injection, G6Pase gene expression began to decline at 6 months for dog E and at 22 months for dog H. The second administration of an HDAd vector delivering a functional G6Pase transgene improved survival and successfully prevented hypoglycemia for an additional 6-28 months in these dogs. The persistence of the HDAd-cG6Pase vector's efficacy for many months in these dogs with GSD-Ia, in contrast with rapidly waning efficacy from AAV2/8 vectors reported here and by Weinstein et al. 9 might be understood based upon each AAV vector genome's composition. Weinstein et al. administered an vector containing the cytomegalovirus enhancer/chicken b-actin promoter to drive G6Pase expression, and this AAV2/8 vector was reported to diminish rapidly when administered to young mice with GSD-Ia in association with cytotoxic T-cell responses in the liver. 21 Therefore, immune responses could have been at least partially responsible for the loss of efficacy by 1 month of age from that AAV2/8 vector. 9 Other, ongoing abnormalities of GSD-Ia could be attributed to the lack of complete efficacy from hepatic correction of G6Pase deficiency with the HDAd-cG6Pase vector, because this vector has partially corrected the deficiency only in liver, but not the kidney, in mice with GSD-Ia. 22 Consistent with a lack of renal correction, the development of frank renal failure in dog E and renal impairment in dog H was observed, which have been reported in both humans and dogs with GSD-Ia. 4, 20 It is noteworthy that the correction of G6Pase deficiency in liver alone following liver transplantation has been insufficient to prevent the progression of renal complications in human patients with GSD-Ia. 23 Growth failure and abnormalities of laboratory testing in GSD-Ia patients and animals may be linked to recurring hypoglycemia and associated nutrient deficiencies. 1, 23, 24 Although the vector-treated dogs had decreased body weights compared with normal controls, these animals demonstrated appreciable body weight gains following HDAd-cG6Pase vector administration. Hypercholesterolemia was partially corrected within the first month of life in the HDAd vector-treated dogs. The plasma lactate levels for the vector-treated dogs were extremely variable. The initial response to vector treatment was a decrease in plasma lactate levels; however, following the early response to vector treatment, plasma lactate values became quite variable and were often elevated during the vectortreated dog's life, resulting in episodic lactic acidemia. It is noteworthy that human patients with GSD-Ia cannot achieve normal blood lactate or cholesterol in the absence of dietary therapy, 1 and that the treated dogs occasionally were found to have normal levels for these two tests without receiving any special dietary therapy. The presence of intermittent lactic acidemia correlated with partial correction of G6Pase deficiency in the liver of HDAd vector-treated dogs with GSD-Ia.
Hepatic G6Pase levels were elevated and hepatic glycogen levels decreased in the HDAd-cG6Pase vector-treated GSD-Ia dogs. We hypothesized that hepatic transgene expression had increased G6Pase activity after rescue vector administration, but our research protocol did not include additional liver biopsies, which prevented confirmation of increased transgene expression following the administration of the serotype 2 HDAd vector. The clinical observations and fasting blood glucose levels were consistent with this hypothesis. The postmortem biopsies obtained following recurrence of hypoglycemia demonstrated marginally increased glycogen content in comparison with earlier biopsies, and this was attributable to the gradual loss of liver transduction over the months following administration of the HDAd vector. We report G6Pase activity per wet weight of homogenized liver in units used for clinical diagnosis of GSD-Ia. Vectortreated dogs were found to have 21% of normal activity (1.5 ± 0.2 mmol g -1 tissue per minute; normal range 7.3 ± 2.2 mmol g -1 tissue per minute), when hypoglycemia was prevented and glycogen storage corrected, 4 to 22 months following HDAd vector administration. The analysis of liver biopsies from these dogs indicated that B20% of normal G6Pase activity might be required to prevent hypoglycemia during fasting. The accompanying reduction of liver glycogen to the normal range did not imply sufficient correction of G6Pase deficiency to prevent lactic acidemia or hypercholesterolemia. We previously found that an AAV2/8 vector achieved correction of G6Pase activity to B80% of the level observed in normal dogs and prolonged survival to 411 months of age without requiring further vector treatment; however, lower G6Pase activity clearly might be sufficient to promote survival. 9 The recurrence of symptoms in two GSD-Ia dogs that survived longer following neonatal HDAd vector signaled a waning of transgene expression. Decreasing G6Pase and increasing glycogen content in the liver of these two dogs in serial liver biopsies confirmed the decreased biochemical correction over time; however, this result is not surprising given experience with HDAd vectors in dogs with hemophilia. 16 In the study by McCormack et al. 16 two dogs with hemophilia A received a 50% greater dose of HDAd vector than administered in the current study, and coagulation factor VIII was elevated transiently to levels approaching the normal range for o2 months. No immune response against factor VIII was detected by inhibitor antibody assay, and therefore the loss of factor VIII expression might be attributed to decreased production in the liver. Indeed, semi-quantitative PCR revealed an approximately twofold decrease in vector genomes over the course of that study. Furthermore, a 33-fold decline in vector genomes between 8 and 30 days following the administration of an HDAd vector to neonatal mice with hemophilia A. 25 These data are consistent with quantitative PCR performed on liver biopsies from 1 to 22 months following HDAd vector administration to three dogs with GSD-Ia, which revealed low numbers of vector genomes. Indeed, accelerated loss of the episomal vector genomes might be expected following the administration of an HDAd vector to dogs during the neonatal period, when active growth and presumably increased cell division is occurring in the liver. In the current study, transgene function was not eliminated in the first month following vector administration, as would be expected if cellular immune responses were mounted against the HDAd vector. Although dog E developed higher titers of anti-Ad2 antibodies (Table 1) , no lymphocytic infiltrates were detected in the liver of dog E to suggest a cytotoxic T lymphocyte response against transduced liver cells (Figure 4c) . Consistent with the hypothesis that episomal vector genomes might be lost following vector administration to neonatal animals with GSDIa, an AAV2/8 vector decreased from 42 copies per liver cell at 3 weeks of age to 0.3 copies per liver cell at 26 weeks of age following administration to 2-week-old G6pase (À/À) mice. 26 Despite the loss of vector genomes, the current data for an HDAd vector that persisted at 40.1 copies per nuclear genome for 6 to 22 months following vector administration to dogs with GSD-Ia are comparable to the former data for an AAV2/8 vector in G6pase (À/À) mice. Chou and colleagues 21 also highlighted the transience of AAV vector-mediated expression by measuring a 12-fold decline in G6Pase expression in mice from age 2-6 weeks. We surmise that the quantity of HDAd vector genomes was higher prior to the time of liver analysis in the current study, consistent with the degree of biochemical correction that was achieved. The ongoing efficacy from the aforementioned AAV2/8 vectors and current HDAd vectors, despite rapid loss of vector genomes in the GSD-Ia liver, suggest that long-lasting G6Pase activity is sufficient to prevent hypoglycemia, reduce liver glycogen storage and prolong survival for many months in animals with GSD-Ia.
Hepatic expression of G6Pase was clearly inadequate to prevent the progression of renal failure, a well-described complication of GSDIa. 1, 20 Renal involvement has been described previously in canine GSD-Ia in the form of focal segmental glomerulosclerosis 4 and tubular necrosis. 9 However, frank renal failure had not been observed until now in canine GSD-Ia.
Long-term survival of dogs with GSD-Ia revealed long-term complications of GSD-Ia with onset earlier than typically reported in human patients with GSD-Ia. These long-term complications occurred despite the prevention of acute hypoglycemia and associated mortality by HDAd vector administration. A preneoplastic liver focus signaled the potential onset of hepatic adenomas, which typically occur during adolescence in GSD-Ia and are known not to be prevented by good metabolic control. 1, 27 Indeed, a patient with 10% of normal G6Pase activity in the liver was recently reported with hepatic adenomas that degenerated to hepatocellular carcinoma despite the absence of any clinical symptoms of hypoglycemia. 28 Cumulatively, the data from HDAd vector-treated dogs with GSD-Ia indicated that prevention of hypoglycemia was insufficient to prevent long-term complications of GSD-Ia.
The success of the HDAd-cG6Pase vector at prolonging survival in dogs with GSD-Ia to the greatest extent to date, up to 36 months, justifies additional preclinical experiments in the anticipation that gene therapy may someday represent a curative therapeutic method in patients with GSD-Ia. The rescue HDAd vector treatment strategy not only corrected hypoglycemia associated with the disease, but also increased survival in two dogs, when compared with untreated, affected GSD-Ia dogs.
MATERIALS AND METHODS

Breeding and neonatal care of puppies
Affected puppies described in this experiment are from Malteagle (MalteseÂ Beagle) and/or Maltihound (MalteseÂBeagleÂHound) carriers. Carrier females were checked weekly for the first signs of proestrus (vulvar swelling and discharge). When the onset of proestrus was detected, vaginal cytology was evaluated daily to determine estrus onset. Blood progesterone levels were monitored to estimate the luteinizing hormone. Females in estrus were then artificially inseminated with semen, freshly collected from carrier males via manual stimulation and were bred daily or on alternate days until the estrus period ended. Pregnancy was determined 25-30 days after day 1 of diestrus by palpation and use of real-time ultrasonography of the abdomen. Abdominal radiographs were taken 1 week prior to the expected due date to determine the size and number of puppies. A small sample of blood was collected from the umbilical cord of each puppy and preserved on a Whatman FTA card (Piscataway, NJ, USA) for DNA analysis of G6Pase status using PCR.
Newborn puppies were monitored every 2 h for nursing activity until genetic status was determined on postnatal day 2. Dextrose was administered to any pup showing clinical signs of hypoglycemia, either orally (50% solution, 1 ml kg -1 ) or subcutaneously (10% solution, 2 ml kg -1 ). Nursing, affected puppies showing clinical signs of hypoglycemia were given supplemental feedings with an oral milk replacement supplement every 2 h (Esbilac, 1 ml per 100 g). Body weights were collected on the day of birth and daily for the first 4 weeks of life. After 4 weeks of life, body weights were obtained monthly. Puppies were weaned at 6 weeks of age.
HDAd vectors
HDAd-G6Pase was constructed as follows. An 11-kb BamHI fragment containing the promoter/enhancer from the human apolipoprotein AI (apoAI) gene was subcloned into the BglII site of modified pLPBL-1 (pLPBL-hgapoAI) was initially developed. 29 A PCR amplified apoAI intron I with these primers: 5¢-C TGCGAGAAGGAGGTGCGTCC-3¢ and 5¢-TCTCGAGTATCGATACGCGTGA ATTCGCGGCCGCGGATCCGAAGGGCCGTGGGGGAC-3¢ and containing the desired enzyme site (underlined) was created. The PCR product was digested with KpnI/XhoI, subcloned into the KpnI/XhoI site of gel-purified pLPBL-hgapoAI (phgapoAI-partial), and then subcloned into the KpnI site of phgAI-partial, resulting in a plasmid containing a human apoAI promoter driven expression cassette (phgAIex). Confirmation of the 2.2-kb KpnI fragment was done by sequencing. The 0.6-kb ClaI fragment containing woodchuck hepatitis virus posttranscriptional regulatory element was subcloned into the ClaI site of the phgAIex (phgAIW), while the canine G6Pase cDNA was excised by BamHI/EcoRI. 4 The canine G6Pase cDNA was subcloned into the BamHI/EcoRI site of phgAIW (pAIW-cG6Pase) and an expression cassette containing the canine G6Pase was excised by AscI digestion. This expression cassette was subcloned into a shuttle vector, pD21 (pD21-AIWcG6Pase), 15 and the empty vector was generated by subcloning a 4.4-kb BamHI fragment of cosmid C346 into pD28. 29 32 Southern blot analysis was used to determine helper virus contamination and vector rearrangement. No helper virus contamination (o0.1%) or vector rearrangement was detected in two independent vector stocks and the ratio of infectious particle to viral particle was 1:18. Endotoxin levels were o2.00 EU ml -1 .
All viral vector stocks were handled according to the Biohazard Safety Level 2 guidelines published by the National Institute of Health.
Vector administration
Following genetic analysis, vectors were administered to affected puppies via jugular venipuncture at 3 days of age. Puppies were anesthetized using isoflurane given by face mask. A central venous catheterization kit with a 24-gauge catheter (AK-04650-3; Arrow International, Reading, PA, USA) was used and inserted into the external jugular vein. The vector was administered via the catheter, at a rate of B1 ml per minute while monitoring vital signs. Total injection volume depended on the puppy's weight and number of vector particles, but was usually between 3 and 8 ml. Following vector administration, treated dogs were monitored every 2-3 h, 24 h per day for clinical signs of hypoglycemia and other clinical abnormalities that might suggest hypoglycemia (lethargy, depression, vomiting, facial twitches, and so on). If clinical signs of hypoglycemia were observed, 10% dextrose (1 ml per 100 g) was administered by mouth.
Feeding
After weaning, GSD-Ia dogs were maintained on an 8-h feeding regimen. Dogs H and Y were offered Science Diet Puppy Dry Food (Topeka, KS, USA) and water ad libitum throughout the day, and at 0700, 1500 and 2300 hours they were offered B100 g of canned Science Diet Canine Growth.
The feeding regimen for the other HDAd vector-treated dog, E, consisted of tube feeding (oral esophageal) 100 ml of food mixture (100 ml Clinicare and one can Iams Eukanuba Restricted Calorie Formula) every 8 h, at 0700, 1500 and 2300 hours.
Liver biopsy and histology
Dogs were anesthetized with isoflurane and a 100-mg liver sample was taken via a lateral right side laparotomy. Half of the 100-mg liver sample was flash frozen in liquid nitrogen and stored at À70 1C, while the remainder was fixed in 10% buffered neutral formalin. Formalin-fixed liver samples were embedded in paraffin, sectioned at 3-6 mm and stained with hematoxylin and eosin, and periodic acid-Schiff to demonstrate glycogen. Microscopic sections were examined by light microscopy by a board certified veterinary pathologist.
Analysis of transduction in liver and kidney
Hepatic G6Pase enzyme analysis was performed by using the flash frozen liver sample taken during liver biopsy as described by Brix et al. 3 A 50-mg sample was weighed and homogenized in deionized water at a volume of 10 ml of cold water per mg of tissue and transferred to a 15-ml conical tube. The sample was sonicated (3Â20 s) and centrifuged at 3000 r.p.m. for 5 min at 4 1C. During preparation of hepatic homogenate in water, the enzyme system is disrupted and the hydrolytic activity of the membrane-bound G6Pase is available for assay. The supernatant was transferred to an Eppendorf tube and centrifuged at 4 1C for 20-30 min at 3000 r.p.m. Following centrifugation, 5 ml of homogenate was placed in four microcentrifuge tubes. Two of the four samples were boiled for 3 min to heat inactivate the enzyme. b-Glycerophosphate was added (45 ml) to a non-boiled and boiled tube, while 45 ml of glucose-6-phosphate was added to the other two tubes. Samples were incubated in a 37 1C water bath for 20 min to allow enzymatic reactions to occur. After 20 min, the samples were boiled for 3 min to stop all reactions. Samples were centrifuged at room temperature for 5 min at 3000 r.p.m. Ultraviolet cuvettes were prepared with 1.0 ml of inorganic phosphorous reagent in each. A 20-ml aliquot of the heatinactivated homogenate samples was added to each cuvette and then incubated for 10 min at room temperature. Samples were run on a UV spectrophotometer (Shimadzu Corporation, Kyoto, Japan). G6Pase activity was measured by using G6P as a substrate after subtraction of non-specific phosphatase activity as estimated by b-glycerophosphate. Glycogen content was measured as described, using the homogenate produced above. 3 Glycogen content was measured by complete digestion of polysaccharide using amyloglucosidase. The structure of the polysaccharide was inferred by using phosphorylase free of debranching enzyme to measure the yield of glucose-1-phosphate. Real-time PCR was performed by standard methods with Syber Green as described 26 to quantify vector genomes using the following primers: HDAd vector detection (cG6P51F: 5¢-GCTGTGCAGCTGAACGTC-3¢; cG6P6R: 5¢-GGCTTTTTCCAGTGTCCA-3¢), and canine b-actin control detection (cb-actinF: 5¢-AGCGGGAAATCGTGCGT GAC-3¢; cb-actinR: 5¢-CAATAGTGATGACCTGCCCGT-3¢). The limit of detection for real-time PCR as performed was 0.001 vector genome/nuclear genome.
Plasma and serum chemistry
Blood samples for routine serum chemistry panels and plasma lactate analysis were collected from affected dogs via the jugular vein with minimal restraint. Samples were placed in a red top tube (serum) and a purple top tube (plasma) and submitted to the clinical pathology laboratory at NC State College of Veterinary Medicine for a complete blood count and chemistry panel. Parameters of interest were serum glucose, cholesterol and lactate. The normal canine reference range for glucose is 60-120 mg dl -1 , and for cholesterol the normal range is 125-300 mg dl -1 .
Heparinized blood samples were analyzed for lactate using a blood gas analyzer (Gem Premier 3000 #14642 manufactured by Instrumentation Laboratory, Bedford, MA, USA). The canine plasma lactate reference range at NC State College of Veterinary Medicine clinical pathology laboratory is 0.4-3.0 mmol l -1 .
Enzyme-linked immunosorbent assay detection of plasma anti-Ad antibodies
Wells were coated with 5Â10 8 Ad serotype 2 or 5 vector particles per well at 4 1C overnight for detection of anti-Ad antibody. After washing with PBS containing 0.05% Tween 20, serial dilutions of the plasma were added to the wells and incubated for 1 h at room temperature. The wells were washed with 0.05% Tween 20+PBS, incubated with a 1:2500 dilution of alkaline phosphatase-conjugated sheep anti-mouse IgG1 at room temperature for 1 h, and washed, and alkaline phosphatase substrate (p-nitrophenyl phosphate) was added. The absorbance at 411 nm was measured with a Tecan SpectraFluor (MTX Lab Systems, Vienna, VA, USA) microplate reader. Each sample was analyzed in duplicate at each dilution. The titer of antibody was determined as the highest dilution at which the value for absorbance exceeded 0.08.
